Multidrug resistance-associated protein transmembrane transporter Research.doc

 PAGE \* MERGEFORMAT 21 Multidrug resistance-associated protein transmembrane transporter Research [Keywords:] tumor The performance of multi-drug resistant tumor cells is often the cause of clinical chemotherapy failure and poor survival prognosis of one of the main. Multi-drug resistance is the main form of drug-resistant tumor cells, tumor multi-drug resistance (multidrug resistance, MDR) refers to a drug acting on the tumor cells to make it resistant to later, the tumor cells gradually right has not been exposed, the structure unrelated to the role of a variety of different targets and mechanisms of antitumor drugs also have cross-resistance. Present study suggests that the molecular mechanism of MDR tumors arise mainly in the following aspects: (1) transmembrane drug pump gene amplification or over-expression of transmembrane transport protein highly expressed, thereby contributing to drug efflux, and subcellular distribution of drugs changes to reduce the drug concentration. (2) metabolic transformation change, such as cell changes in some of the protease caused the cells to enhance the detoxification function. (3) changes in drug targets, such as the ribozyme DNA topoisomerase Ⅱ (topoisomerase Ⅱ , TOPO Ⅱ ) content decreases or the nature of change, leading to TOPO Ⅱ as the target of the anticancer drug resistance. (4) other mechanisms, including changes in apoptosis-related pathways, cell proliferation rate of change, damage and repair to strengthen and in vivo pharmacokinetics and changes in the factors. A variety of these mechanisms often co-exist, but more in a mainly different mechanisms at the same time often influence each other. The mechanism of MDR in recent years in the transmembrane transport proteins deepening, has found a P-glycoprotein (P-glycoprotein, P-gp), multidrug resistance protein (multidrug resistance pro-tein, MRP), lung resistance Drug-associated protein (the lung resistance-related protein, LRP), breast cancer resistance prote